6 assets in Central Nervous System Non-Hodgkin Lymphoma

Therapeutic assets addressing Central Nervous System Non-Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ibrutinib Central Nervous System Non-Hodgkin Lymphoma	Memorial Sloan Kettering Cancer Center	P2	B (63)
Rituximab Central Nervous System Non-Hodgkin Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P2	B (60)
Methotrexate Central Nervous System Non-Hodgkin Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (55)
Orelabrutinib Central Nervous System Non-Hodgkin Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (53)
Btk-In-24 Central Nervous System Non-Hodgkin Lymphoma	Nurix Therapeutics, Inc.	P1	CC (43)
Epcoritamab Central Nervous System Non-Hodgkin Lymphoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)